Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

BACKGROUND: BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to comparatively assess efficacy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Alexeev, Sergey M., Khorinko, Andrey V., Mukhametshina, Guzel Z., Shelepen, Konstantin G., Burdaeva, Olga N., Kulik, Sergey A., Satheesh, Chiradoni Thugappa, Srivastava, Kirti, Vikranth, Mummaneni, Kryukov, Fedor, Paltusova, Anastasia N., Shustova, Mariya S., Ivanov, Roman A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7439710/
https://ncbi.nlm.nih.gov/pubmed/32819305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07247-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados